Spiriva respimat and Abilify drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Spiriva respimat (tiotropium bromide) and Abilify (aripiprazole). Common drug interactions include confusional state among females and cardiac failure congestive among males.

The phase IV clinical study analyzes what interactions people have when they take Spiriva respimat and Abilify. It is created by eHealthMe based on reports of 42 people who take the same drugs from the FDA, and is updated regularly.

What is Spiriva respimat?

Spiriva respimat has active ingredients of tiotropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 9,788 Spiriva respimat users. Check the latest studies of Spiriva respimat.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,455 Abilify users. Check the latest studies of Abilify.



On Aug, 06, 2026

42 people who take Spiriva respimat and Abilify together, and have interactions are studied.

Spiriva respimat and Abilify drug interactions.

What are the common drug interactions of Spiriva Respimat and Abilify, by gender? *:

female:

  1. Confusional state
  2. Disorientation (disability in which the senses of time, direction, and recognition of people and places)
  3. Dizziness
  4. Drug abuse
  5. Drug hypersensitivity
  6. Dry skin
  7. Dyspnoea (difficult or laboured respiration)
  8. Eye disorder
  9. Fibromyalgia (a long-term condition which causes pain all over the body)
  10. Flushing (the warm, red condition of human skin)

male:

  1. Cardiac failure congestive
  2. Drug level decreased
  3. Bacteraemia (presence of bacteria in the blood)
  4. Cellulitis (infection under the skin)
  5. Death
  6. Dyspnoea (difficult or laboured respiration)
  7. Fatigue (feeling of tiredness)
  8. Feeling hot
  9. Feeling jittery
  10. Hyperhidrosis (abnormally increased sweating)

What are the common drug interactions of Spiriva Respimat and Abilify, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Akathisia (a movement disorder characterized by a feeling of inner restlessness)
  2. Nerve injury
  3. Restlessness (not able to rest)

30-39:

n/a

40-49:

  1. Mobility decreased (ability to move is reduced)
  2. Nasopharyngitis (inflammation of the nasopharynx)
  3. Nausea (feeling of having an urge to vomit)
  4. Oedema peripheral (superficial swelling)
  5. Oropharyngeal pain
  6. Oxygen saturation decreased
  7. Pain
  8. Productive cough
  9. Pruritus (severe itching of the skin)
  10. Rash

50-59:

  1. Cardiac failure congestive
  2. Dyspnoea exertional (breathlessness or shortness of breath)
  3. Pulmonary hypertension (increase in blood pressure in the lung artery)
  4. Dyspnoea (difficult or laboured respiration)
  5. Hospitalisation
  6. Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
  7. Acute respiratory failure
  8. Arthralgia (joint pain)
  9. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  10. Asthenia (weakness)

60+:

  1. Drug level decreased
  2. Suicidal ideation
  3. Diarrhoea
  4. Drug abuse
  5. Drug hypersensitivity
  6. Dry skin
  7. Fall
  8. Fluid retention (an abnormal accumulation of fluid in the blood)
  9. Headache (pain in head)
  10. Hemiparesis (weakness on one side of the body)

What are the existing conditions these people have? *

  1. Stress And Anxiety: 9 people, 21.43%
  2. Oedema (fluid collection in tissue): 9 people, 21.43%
  3. Memory Loss: 9 people, 21.43%
  4. Headache (pain in head): 9 people, 21.43%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 9 people, 21.43%
  6. Enlarged Prostate: 9 people, 21.43%
  7. Back Pain: 9 people, 21.43%
  8. Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 9 people, 21.43%
  9. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 8 people, 19.05%
  10. Bipolar Disorder (mood disorder): 8 people, 19.05%

* Approximation only. Some reports may have incomplete information.

Do you take Spiriva respimat and Abilify?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Spiriva respimat and Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Spiriva respimat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Spiriva respimat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Abilify and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on tiotropium bromide and aripiprazole (the active ingredients of Spiriva respimat and Abilify, respectively), and Spiriva respimat and Abilify (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: